G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment

Autor: Martinez Sanz, Paula, van Rees, Dieke J, van Zogchel, Lieke M J, Klein, Bart, Bouti, Panagiota, Olsman, Hugo, Schornagel, Karin, Kok, Ivana, Sunak, Ali, Leeuwenburg, Kira, Timmerman, Ilse, Dierselhuis, Miranda P, Kholosy, Waleed M, Molenaar, Jan J, van Bruggen, Robin, van den Berg, Timo K, Kuijpers, Taco W, Matlung, Hanke L, Tytgat, Godelieve A M, Franke, Katka, Afd Pharmaceutics, Pharmaceutics

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)
Journal for ImmunoTherapy of Cancer, 9(5), 1. BioMed Central Ltd.
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, 9(5), 1. BioMed Central
Journal for immunotherapy of cancer, 9(5):e002259. BioMed Central Ltd.

BackgroundCurrent immunotherapy for patients with high-risk neuroblastoma involves the therapeutic antibody dinutuximab that targets GD2, a ganglioside expressed on the majority of neuroblastoma tumors. Opsonized tumor cells are killed through antibo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0a8c22e38a8b458ee9e9cfac080fa47
https://doi.org/10.1136/jitc-2020-002259